title: Long-term linear growth of children with severe steroid-responsive nephrotic syndrome.
abstract: The present study was designed to evaluate the risk of permanent linear growth impairment in a selected group of 42 children with steroid-dependent nephrotic syndrome (SDNS) and 14 children with frequently relapsing nephrotic syndrome (FRNS). Longitudinal height measurements were available in all patients from the onset of the disease for a mean follow-up of 11.7+/-3.5 years. During the prepubertal period, patients lost 0.49+/-0.6 height SD score (HtSDS) ( P<0.001). Twenty-three patients have reached their final height with an average loss of 0.92+/-0.8 HtSDS from the onset of their disease ( P<0.001) and 0.68+/-0.7 from their target HtSDS ( P<0.001). The pubertal growth spurt was mildly delayed in male but not female patients. Steroid therapy, calculated as the mean duration of prednisone (PDN) treatment or as the average cumulative PDN dose, was the only predictor of poor growth evolution. Partial catch-up growth occurred after PDN withdrawal. Children with early onset NS and adolescent patients, who were still receiving PDN after the age of 9 years in girls and 11 years in boys, were at higher risk for HtSDS loss. In conclusion, children with severe steroid-responsive NS are at risk of permanent growth retardation secondary to prolonged courses of steroid treatment.
authors.affiliation: Division of Nephrology, Children's Hospital and Research Institute Bambino Gesu', Piazza S. Onofrio 4, 00165 Rome, Italy. emma@opbg.net
authors.forename: Francesco
authors.initials: F
authors.lastname: Emma
authors.forename: Antonella
authors.initials: A
authors.lastname: Sesto
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Rizzoni
mesh_terms: D000293:Adolescent; D000328:Adult; D001827:Body Height / Q000187:drug effects; D002648:Child; D002657:Child Development / Q000187:drug effects*; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000009:adverse effects*; D006130:Growth Disorders / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D007223:Infant; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000453:epidemiology; D011239:Prednisolone / Q000009:adverse effects*; D012307:Risk Factors
chemical_list: D005938:Glucocorticoids; D011239:Prednisolone